TY - JOUR
T1 - Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infection (HELP)
T2 - Study protocol for a multicentre stepped-wedge cluster randomised trial
AU - Hagel, Stefan
AU - Gantner, Julia
AU - Spreckelsen, Cord
AU - Fischer, Claudia
AU - Ammon, Danny
AU - Saleh, Kutaiba
AU - Phan-Vogtmann, Lo An
AU - Heidel, Andrew
AU - Müller, Susanne
AU - Helhorn, Alexander
AU - Kruse, Henner
AU - Thomas, Eric
AU - Rißner, Florian
AU - Haferkamp, Silke
AU - Vorwerk, Jens
AU - Deffge, Saskia
AU - Juzek-Küpper, Marc Fabian
AU - Lippmann, Norman
AU - Lübbert, Christoph
AU - Trawinski, Henning
AU - Wendt, Sebastian
AU - Wendt, Thomas
AU - Dürschmid, Andreas
AU - Konik, Margarethe
AU - Moritz, Stefan
AU - Tiller, Daniel
AU - Röhrig, Rainer
AU - Schulte-Coerne, Jonas
AU - Fortmann, Jonas
AU - Jonas, Stephan
AU - Witzke, Oliver
AU - Rath, Peter Michael
AU - Pletz, Mathias W.
AU - Scherag, André
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/2/10
Y1 - 2020/2/10
N2 - Staphylococci are the most commonly identified pathogens in bloodstream infections. Identification of Staphylococcus aureus in blood culture (SAB) requires a prompt and adequate clinical management. The detection of coagulase-negative staphylococci (CoNS), however, corresponds to contamination in about 75% of the cases. Nevertheless, antibiotic therapy is often initiated, which contributes to the risk of drug-related side effects. We developed a computerised clinical decision support system (HELP-CDSS) that assists physicians with an appropriate management of patients with Staphylococcus bacteraemia. The CDSS is evaluated using data of the Data Integration Cent ers (DIC) established at each clinic. DICs transform heterogeneous primary clinical data into an interoperable format, and the HELP-CDSS displays information according to current best evidence in bacteraemia treatment. The overall aim of the HELP-CDSS is a safe but more efficient allocation of infectious diseases specialists and an improved adherence to established guidelines in the treatment of SAB. Methods and analysis The study is conducted at five German university hospitals and is designed as a stepped-wedge cluster randomised trial. Over the duration of 18 months, 135 wards will change from a control period to the intervention period in a randomised stepwise sequence. The coprimary outcomes are hospital mortality for all patients to establish safety, the 90-day disease reoccurrence-free survival for patients with SAB and the cumulative vancomycin use for patients with CoNS bacteraemia. We will use a closed, hierarchical testing procedure and generalised linear mixed modelling to test for non-inferiority of the CDSS regarding hospital mortality and 90-day disease reoccurrence-free survival and for superiority of the HELP-CDSS regarding cumulative vancomycin use. Ethics and dissemination The study is approved by the ethics committee of Jena University Hospital and will start at each centre after local approval. Results will be published in a peer-reviewed journal and presented at scientific conferences. Trial registration number DRKS00014320.
AB - Staphylococci are the most commonly identified pathogens in bloodstream infections. Identification of Staphylococcus aureus in blood culture (SAB) requires a prompt and adequate clinical management. The detection of coagulase-negative staphylococci (CoNS), however, corresponds to contamination in about 75% of the cases. Nevertheless, antibiotic therapy is often initiated, which contributes to the risk of drug-related side effects. We developed a computerised clinical decision support system (HELP-CDSS) that assists physicians with an appropriate management of patients with Staphylococcus bacteraemia. The CDSS is evaluated using data of the Data Integration Cent ers (DIC) established at each clinic. DICs transform heterogeneous primary clinical data into an interoperable format, and the HELP-CDSS displays information according to current best evidence in bacteraemia treatment. The overall aim of the HELP-CDSS is a safe but more efficient allocation of infectious diseases specialists and an improved adherence to established guidelines in the treatment of SAB. Methods and analysis The study is conducted at five German university hospitals and is designed as a stepped-wedge cluster randomised trial. Over the duration of 18 months, 135 wards will change from a control period to the intervention period in a randomised stepwise sequence. The coprimary outcomes are hospital mortality for all patients to establish safety, the 90-day disease reoccurrence-free survival for patients with SAB and the cumulative vancomycin use for patients with CoNS bacteraemia. We will use a closed, hierarchical testing procedure and generalised linear mixed modelling to test for non-inferiority of the CDSS regarding hospital mortality and 90-day disease reoccurrence-free survival and for superiority of the HELP-CDSS regarding cumulative vancomycin use. Ethics and dissemination The study is approved by the ethics committee of Jena University Hospital and will start at each centre after local approval. Results will be published in a peer-reviewed journal and presented at scientific conferences. Trial registration number DRKS00014320.
KW - antibiotic stewardship
KW - clinical decision support system
KW - healthcare interoperability standards
KW - staphylococcus bacteremia
UR - http://www.scopus.com/inward/record.url?scp=85079339883&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2019-033391
DO - 10.1136/bmjopen-2019-033391
M3 - Article
C2 - 32047014
AN - SCOPUS:85079339883
SN - 2044-6055
VL - 10
JO - BMJ Open
JF - BMJ Open
IS - 2
M1 - e033391
ER -